Actively Recruiting
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
Led by Sunnybrook Health Sciences Centre · Updated on 2024-04-12
30
Participants Needed
1
Research Sites
545 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.
CONDITIONS
Official Title
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status 0-1
- Histologic confirmation of prostate adenocarcinoma
- Documented metastatic castration-resistant prostate cancer
- Currently treated with abiraterone
- Evidence of oligoprogression with 5 progressing metastatic lesions (no more than 3 in any one organ system) while other metastases are controlled or responding
- All metastases suitable for SABR treatment
You will not qualify if you...
- Unequivocal clinical progression requiring opioid therapy for cancer pain
- Immediate need for cytotoxic chemotherapy as determined by physician
- ECOG performance status deteriorated to grade 3
- Evidence of spinal cord compression
- Prior malignancy within the past 5 years, except non-melanoma skin cancer and in-situ cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Odette Cancer Centre
Toronto, Ontario, Canada, M4N3M5
Actively Recruiting
Research Team
U
Urban Emmenegger, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here